JP2017531646A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531646A5
JP2017531646A5 JP2017518070A JP2017518070A JP2017531646A5 JP 2017531646 A5 JP2017531646 A5 JP 2017531646A5 JP 2017518070 A JP2017518070 A JP 2017518070A JP 2017518070 A JP2017518070 A JP 2017518070A JP 2017531646 A5 JP2017531646 A5 JP 2017531646A5
Authority
JP
Japan
Prior art keywords
hal
cor
conr
independently
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017518070A
Other languages
English (en)
Japanese (ja)
Other versions
JP6662865B2 (ja
JP2017531646A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/001973 external-priority patent/WO2016050358A1/en
Publication of JP2017531646A publication Critical patent/JP2017531646A/ja
Publication of JP2017531646A5 publication Critical patent/JP2017531646A5/ja
Application granted granted Critical
Publication of JP6662865B2 publication Critical patent/JP6662865B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017518070A 2014-10-01 2015-10-01 ボロン酸誘導体 Active JP6662865B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14003389.5 2014-10-01
EP14003389 2014-10-01
PCT/EP2015/001973 WO2016050358A1 (en) 2014-10-01 2015-10-01 Boronic acid derivatives

Publications (3)

Publication Number Publication Date
JP2017531646A JP2017531646A (ja) 2017-10-26
JP2017531646A5 true JP2017531646A5 (enExample) 2019-10-17
JP6662865B2 JP6662865B2 (ja) 2020-03-11

Family

ID=51751859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518070A Active JP6662865B2 (ja) 2014-10-01 2015-10-01 ボロン酸誘導体

Country Status (21)

Country Link
US (1) US10669289B2 (enExample)
EP (1) EP3201206B1 (enExample)
JP (1) JP6662865B2 (enExample)
KR (1) KR102457840B1 (enExample)
CN (1) CN107001391B (enExample)
AU (1) AU2015327345B9 (enExample)
BR (1) BR112017006622A2 (enExample)
CA (1) CA2963203A1 (enExample)
CL (1) CL2017000792A1 (enExample)
DK (1) DK3201206T3 (enExample)
ES (1) ES2761774T3 (enExample)
IL (1) IL251302B (enExample)
MX (1) MX372823B (enExample)
MY (1) MY186911A (enExample)
NZ (1) NZ730981A (enExample)
PH (1) PH12017500293A1 (enExample)
RU (1) RU2717558C2 (enExample)
SG (1) SG11201702628XA (enExample)
UA (1) UA122672C2 (enExample)
WO (1) WO2016050358A1 (enExample)
ZA (1) ZA201703007B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016050356A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
RU2017115188A (ru) 2014-10-01 2018-11-06 Мерк Патент Гмбх Производные бороновой кислоты
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
CA2963186A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
HUE054460T2 (hu) * 2017-01-18 2021-09-28 Principia Biopharma Inc Immunproteaszóma-gátlók
PT3672977T (pt) 2017-08-24 2022-09-23 Merck Patent Gmbh Derivados do ácido borónico
CN111065619B (zh) * 2017-08-29 2022-08-12 浙江海正药业股份有限公司 (E)-α,β-不饱和酰胺化合物及其制备方法和用途
WO2019075386A1 (en) * 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
RS63666B1 (sr) 2017-11-16 2022-11-30 Principia Biopharma Inc Inhibitori imunoproteazoma
EP3710458A1 (en) 2017-11-16 2020-09-23 Principia Biopharma Inc. Immunoproteasome inhibitors
IL280376B2 (en) 2018-07-26 2024-08-01 Merck Patent Gmbh Boronic acid derivatives, their preparation and pharmaceutical compositions containing them
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
EP4377324A1 (en) 2021-07-29 2024-06-05 Merck Patent GmbH Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain
JP7734276B2 (ja) * 2021-10-14 2025-09-04 ショウヤオ ホールディングス(ベイジン) カンパニー, リミテッド ボロン酸誘導体
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658885A (en) * 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
US5462964A (en) * 1993-10-20 1995-10-31 The Du Pont Merck Pharmaceutical Company Dipeptide boronic acid inhibitors of trypsin-like enzymes
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
AU5788800A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
DK1400245T3 (da) * 2002-09-09 2006-08-28 Trigen Ltd Borsyresalte anvendelige til parenterale formuleringer til selektiv thrombininhibering
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN1867572B (zh) * 2003-08-14 2012-03-28 赛福伦公司 蛋白酶体抑制剂及其使用方法
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AU2011242794B2 (en) 2010-04-22 2016-11-24 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
CA2860142C (en) 2011-12-22 2020-10-27 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
SG10201908467RA (en) 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
CA2963186A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
RU2017115188A (ru) 2014-10-01 2018-11-06 Мерк Патент Гмбх Производные бороновой кислоты
JP6732736B2 (ja) 2014-10-01 2020-07-29 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウィルス複製阻害剤としての一または二置換インドール誘導体
EP3201177B1 (en) 2014-10-01 2018-11-21 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indoles as dengue viral replication inhibitors
NO2721243T3 (enExample) 2014-10-01 2018-10-20
WO2016050356A1 (en) 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives

Similar Documents

Publication Publication Date Title
JP2017531646A5 (enExample)
JP2018502048A5 (enExample)
JP2017536335A5 (enExample)
AR104963A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
MX380928B (es) Inhibidores de kras g12c.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
CO2018004800A2 (es) Antagonistas del receptor muscarinico 4 y metodos de uso.
JP2016515561A5 (enExample)
CY1123451T1 (el) Αγωνιστες τριαζολης του υποδοχεα αρj
CL2019002150A1 (es) Derivados de 3-fenil-4-amino-imidazo[4,5-c]piridin-2-ona y 7-fenil-6-amino-purin-8-ona sustituidos, inhibidores de tirosinacinasas, en particular tirosinacinasa de bruton (btk); composiciones que contiene los compuestos; y uso para enfermedades tales como cáncer, autoinmunitarias, inflamatorias y tromboembólicas. (divisional solicitud 201703073)
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
DOP2022000053A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
CY1124680T1 (el) Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου
MX2019013954A (es) Inhibidores covalentes de kras.
AR088748A1 (es) Macrociclos como inhibidores del factor xia
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
EA201791066A1 (ru) Твердые формы ингибитора ask1
EA201991884A2 (ru) Ингибиторы g12c kras
JP2018525441A5 (enExample)
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
AR110088A1 (es) Inhibidores de magl
AR117189A1 (es) Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
MX374401B (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso para tratar cancer.